By Dhirendra Tripathi

Investing.com — Stocks rose on the first trading day of 2022, fueled by Apple’s climb above $3 trillion in market value, the first-ever to reach that milestone.

Markets were hoping to continue their rally in the new year. Tesla shares rose 9.9% on the news that Tesla’s fourth quarter deliveries were well ahead of Wall Street estimates, even though there was a shortage in chips.

Even airline stocks were on the rise despite the cancellation of thousands of flights over the New Year’s weekend, when travelers were trying to return home from holiday trips. These cancellations and delays were caused by winter weather that slowed airports on the East Coast, Midwest, and East Coasts, as well as staff shortages due to Covid cases.

Wall Street’s principal indexes closed 2021 with significant monthly, quarterly, and annual gains. They also recorded their greatest three-year increase since 1999. Reuters reports Monday.

With 70 records-breaking closes, the market grew 27% in 2013.

It’s a light week for data and earnings, though Tuesday will see the latest job openings report.

These are the three factors that will impact markets tomorrow.

1. Tesla deliveries

While the news of Tesla Inc (NASDAQ:)’s successful fourth quarter in terms of vehicles delivered came out over the weekend, the stock reacted positively on Monday and was likely to continue to react on Tuesday. The strong demand in electric vehicles was reflected by the ADRs and stocks of Chinese counterparts.

Tesla shipped 308,600 cars in its fourth quarter. This was significantly more than the analysts expected of 263,026 vehicles.

2. Apple’s meteoric rise

Apple Inc (NASDAQ) shares reached the $3 trillion threshold of market value Monday. This was just one year after the company’s $2 trillion milestone. Despite the shortage of chips, Apple Inc (NASDAQ:) shares have shown remarkable resilience throughout the reopening trade. Analysts think it sold record numbers of iPhones in the quarter. More positive news from virtual reality headsets is anticipated this year.

3. Vaccine news

Pfizer Inc (NYSE:) continued its momentum after the U.K.’s approval of the company’s Covid-19 pill, which boosts chances of the oral drug finding wider acceptance amid omicron surge.

The Medicines and Healthcare products Regulatory Agency’s nod came Friday. The pill already has the U.S. Food and Drug Administration’s approval.

In the meantime Moderna Inc (NASDAQ:) stock got dinged after the FDA expanded the use of the Covid-19 booster shots made by rivals  Pfizer and BioNTech SE (NASDAQ:) for younger teenagers. 

—This report was contributed by Investing.com employees